A thirteen-chapter audio walkthrough of the ecosystem, the simulators and the opportunity. Choose your language and press play.
Twelve pages, one logic: first the story, then the products, then the numbers, then the paperwork. Use this map any time you feel lost — every card says exactly what the page is for and what you can do there.
Why precision health, why the Gulf, why now — the investment logic in plain language.
The narrated walkthrough in four languages, plus galleries of every real product and system.
The nine revenue lines side by side: what each sells, to whom, at what margin.
How revenue compounds: clinics, reports, subscriptions and licences stacking year over year.
The interactive model: move clinics, price, churn and capital and watch ARR, valuation and your stake react live.
Your personal outcome: enter a ticket size and see dilution, multiple and exit scenarios.
How the company is priced: comparables, multiples and the bridge from today's ARR to the target value.
The fundraising journey: what is open now, instrument, size, valuation and terms.
Exactly where the capital goes, line by line, and what each euro is expected to return.
Country master licences: the asset-light way to enter a new market with us.
The full slide deck, including the glossary of every financial term used on this site.
Disclaimers, structure and regulatory notes for this material.
One platform. Ten products. Compounding from day one.
Welcome, and thank you for being here. You are about to see something rare: not ten separate startups, but one biological intelligence platform expressed through ten outstanding products across four powerful verticals. Everything you will see in the next minutes is live, interactive and built for investors who want proof, not promises. Let's begin.
Our own epigenetic age algorithm, validated in our clinics. Patients see their biological age drop — and return twice a year to prove it.
Population-scale methylation insight sold to pharma, insurers and governments — a B2G revenue line no consumer test company owns.
One genome automatically becomes a personalised supplement, a DNA cosmetic and a Veneer oral protocol. Three recurring products from a single test.
Pathway360 and Campusverse certify the doctors who prescribe our protocol — an exclusive channel competitors must build from zero.
A curated genomic database and quarter-century of validated protocols — the one asset capital alone cannot accelerate.
Science-led, DNA-matched formulations with 80%+ gross margin and a monthly repurchase cycle across pharmacies, dentists and marketplaces.
Where our proprietary technology creates pricing power, margin and defensibility that generic testing companies cannot copy.
Proprietary RobAge clock, validated on our own methylation cohort
Licensed third-party clocks, identical across all competitors
AI interpretation engine: genome to clinical report in minutes
Manual specialist review, days of turnaround, linear headcount cost
One genome, ten products across clinical, consumer and licensing
Single-test businesses with one-off transactions
Genotype-to-formula engine producing personalised SKUs on demand
Fixed catalogue supplements marketed as 'personalised'
Longitudinal methylation and outcome data owned by the holding
Data held by the sequencing vendor or discarded after delivery
Master-license model: partners fund local operations and pay royalties
Capital-intensive owned labs in every new country
The AI interpretation engine turns raw sequencing into a physician-grade report in minutes instead of days, in four languages.
Automation removes the manual bottleneck, so one clinical team can serve an entire country without linear hiring.
Suggests the exact pathway, formula and follow-up date per patient, so outcomes no longer depend on which doctor you meet.
AI drives supplement, cosmetic and Veneer formulation, lifting retention because the product is literally made for one person.
Campusverse trains and certifies doctors globally with AI tutoring, turning education into a distribution engine.
More customers make the models sharper and cheaper — the flywheel a newcomer cannot start without our data.
Follow one real customer journey through the RobGenes AI pipeline. Every step adds margin, data and lifetime value.
Saliva kit plus a structured digital health questionnaire.
AI validates completeness, flags contraindications and pre-assigns the clinical pathway before the lab even starts.
Clean, structured case file with zero manual triage.
Test sale booked: first revenue event.
Interpretation engine, clinical co-pilot, enterprise API — the shared cost reused by all ten products.
GMP production, packaging and retail launch of the 80%+ margin, monthly-repurchase products.
Licensed sites and master licensees across the Gulf and Europe, financed partly by the licensees themselves.
Pathway360 and Campusverse cohorts — each certified doctor becomes a recurring distribution node.
Every product mentioned in this tutorial already exists, is priced, and is sold today across the UAE and Saudi Arabia.
These are the actual consumer and clinical apps of the group — live software, not concepts.
The interpretation layer between raw methylation arrays and clinical action: probe → gene → condition mapping, a transparent risk model, AI long-form clinical reports and biological-age tracking — under 5 minutes from upload to report.
Raw DNA, blood biomarkers and a structured anamnesis become a colour-coded metabolic-pathway map and three printable, clinic-branded report families in 11 languages. What takes a physician 3–6 hours of manual interpretation is produced in minutes — with deterministic safety rails.
A multi-clinic white-label platform with 12 clinical modules — genomics and 3D signature, target exome, PGx, functional nutrition, RoBioAge, methylation, longevity, skin, cosmetic personalisation and an AI concierge — operated today by real clinics in the UAE, Brazil and Europe.
Turns a genetic test into a daily companion: the same DNA profile is reinterpreted every day against the latest labs, check-ins, food, sleep and stress. Not a PDF — a living prevention system with a private AI coach.
Monetises the raw DNA files millions of consumers already own: 45+ admixture models including proprietary RJ/RJ2/RJ3/IN1 panels, verified relative matching, and AI-written ancestral narratives with historical imagery — no kit, no lab, no shipping.
A deterministic drug–gene engine: it reads any raw DNA file, calls star-allele haplotypes, assigns metabolizer phenotypes and returns prescribing guidance per drug — with a full evidence trail and clinic-branded PDF in EN/PT/AR/TR. In daily use by partner clinics in the UAE, Brazil and Europe.
Twenty-plus branded clinical panels generated from one DNA ingestion — cardiovascular, neurology, mental health, longevity, skin, nutrition, detoxification and more. Each is a full editorial A4 report with radar charts, ranked findings, patient-friendly explanations and clinic-named disclaimers, in EN/PT/AR/TR. Ingestion is paid once; every extra panel is near-pure margin.
Clinical-grade triage of a patient's entire genotyped exome against a curated 600k-variant clinical reference — tens of thousands of hits reduced to the handful that actually change care, with strand-aware zygosity, significance gating and population frequency context. No new sequencing: every raw file a clinic already owns becomes a new billable deliverable.
Live STEM teaching platform: infinite collaborative whiteboard, 69 ready simulators, a 3D chemistry lab with 28 real reactions, a real physics engine, and an AI co-teacher that draws, computes, explains and narrates in 5 languages. Runs in the browser on any screen — a published product, not a prototype.
Adjacent lines already in production or pilot.
RobGenes Campus: an immersive 3D world where physicians and students train inside the science — education as a recurring channel.
In-house production of DNA-matched supplement formulas — margin captured from prescription to bottle.
Skincare formulated against each client's genetic profile — high-margin recurring beauty revenue.
Methylation-based testing run in our own lab: biological age, exposure and reversibility markers.
Robotic sample handling and AI process control — scaling throughput without scaling headcount.
These are the actual systems running right now — not mock-ups. Open any of them and audit the numbers yourself.
Move the round size and allocation, watch revenue, margin, runway and recurring mix recalculate live.
Open ›
The full narrative deck: market, products, unit economics, roadmap, glossary and the round itself.
Open ›
Private access request, documentation index and the direct line to the founder.
Open ›
Stress-test entry price, dilution and exit multiples before you commit a single dollar.
Open ›
How acquisition, retention and cross-sell compound across the ten products.
Open ›
The ten revenue lines, each with its own margin profile and recurring engine.
Open ›
Why one biological platform beats ten separate startups — the logic behind the holding.
Open ›
The full journey from $1.2M ARR today to a global public holding, round by round.
Open ›
Exactly where each dollar goes and which milestone it unlocks.
Open ›
Master licences per country: entry fees plus revenue share, with no capex from us.
Open ›Laboratories, hospitals and clinic groups already running RobGenes technology with their own patients.
Each company carries its own identity, market and revenue model — all running on the same biological data engine.
Set the round size and allocate every dollar across the five engines. The model recalculates ARR, recurring share, valuation and investor ROI instantly.
Interpretation engine, RobAge models, automation of every report.
$2.1MPersonalised supplement line, subscriptions, D2C acquisition.
$1.5MPhysician network, clinical validation, higher-ticket protocols.
$1.2MMaster licences funded by partners, royalties with no local capex.
$0.7MAudit, compliance, IP protection and the path to a public holding.
$0.5MIllustrative model for discussion only. Not a forecast, offer or guarantee of returns.
$1.2M ARR today from live clinics and products — you are funding acceleration, not discovery.
You invest at holding level, which owns the IP, the platform and the international licences — diversified by design.
Memberships, retests and monthly consumer products push gross margin above 80% on the fastest-growing lines.
The same AI platform cost is reused in every new market, so each country launch is cheaper than the last.
Diagnostics labs, supplement majors, longevity groups, AI health platforms — or a public listing.
Every risk named, scored, mitigated and budgeted — and every assumption testable in the live simulator.
Answer three questions and we route you to the opportunity built for your profile — then request private access.
Open the simulator, stress-test every assumption, then talk to us about the round.